Serrapeptase API Manufacturers & Suppliers

Serrapeptase (CAS Number 95077-02-4) is a proteolytic enzyme derived from Serratia species, primarily investigated for its potential use as an adjunct treatment in osteoarticular infections. It is commonly administered concomitantly with antibiotics, aiming to support management of inflammation and tissue degradation associated with these conditions.

Currently, serrapeptase is classified as an investigational agent without specific global regulatory approval for any formal clinical indication. Ongoing research includes clinical trials such as NCT02493179, which evaluates its efficacy in reducing inflammation following third molar (wisdom tooth) surgery. Despite its inclusion in categories such as analgesics, non-narcotic analgesics, anti-inflammatory agents, and antirheumatic agents, comprehensive pharmacodynamics and precise mechanisms of action remain to be fully elucidated.

Mechanistically, serrapeptase is known to exert proteolytic activity by hydrolyzing peptide bonds, which may contribute to its potential anti-inflammatory and fibrinolytic effects, although detailed pathways in human physiology are still under investigation. This protease activity is hypothesized to facilitate the breakdown of inflammatory mediators or necrotic tissue, potentially aiding in symptom relief and resolution of infection-associated inflammation.

Key absorption, distribution, metabolism, and excretion (ADME) parameters, as well as detailed safety and toxicity profiles, have not been extensively characterized through robust clinical studies to date. The enzyme’s safety profile reported in investigational use indicates consideration for possible allergic reactions or hypersensitivity, as with other proteolytic enzymes, but conclusive safety data remain limited.

Notable usage contexts are primarily investigational and adjunctive in nature, with no internationally standardized dosing or formulation guidelines. The Serodase brand, offering a 5 mg tablet formulation, is one of the preparations currently under clinical evaluation.

For API procurement, sourcing high-purity serrapeptase is crucial due to its enzymatic nature and potential variability. Suppliers should provide detailed certificates of analysis confirming enzyme activity, microbial testing, and contaminant limits. Consistency in API quality directly impacts formulation stability and clinical reproducibility, underscoring the importance of rigorous supplier qualification and adherence to current good manufacturing practices (cGMP).